Oric® Pharmaceuticals宣布Oric-944 1B期临床试验的剂量探索部分已完成,并继续展现出潜在的最佳疗效与安全性。
Oric® Pharmaceuticals宣布Oric-944 1B期临床试验的剂量探索部分已完成,并继续展现出潜在的最佳疗效与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.